Expression and clinical significance of phosphorylated AKT and phosphatase and tensin homolog in colorectal carcinoma / 肿瘤研究与临床

Objective To study the expression and clinical significance of phosphorylated AKT (pAKT) and phosphatase and tensin homolog (PTEN) in colorectal carcinoma tissues.Methods The expression of pAKT and PTEN were detected by immunohistochemical SP method in 112 case of colorectal carcinomas tissue.Results The positive rates of pAKT and PTEN expression were 79.5 ％ (89/112) and 47.3 ％ (53/112) in colorectal cancerous tissues,respectively,which showed a statistically significance when compared with those in adjacent normal and adenoma tissues.The positive rate of pAKT expression was closely related with the invasive depth,clinical staging and lymph node metastasis of colorectal carcinomas.The positive expression of PTEN was also closely related with the invasive depth,degree of differentiation,clinical staging and lymph node metastasis of colorectal carcinomas.The expressions of pAKT and PTEN were negative correlaed.Conclusion The results showed that the expression of pAKT and PTEN were closely related with progression and metastasis of colorectal carcinomas,which may provide a new therapeutic target for colorectal carcinomas by blocking PTEN/PI3K/AKT signaling pathway.

The clinical observation of hepatic toxicity in hepatitis B virus markers positive cancer patients undergoing chemotherapy / 中国医师进修杂志

Objective To evaluate the liver damage induced by chemotherapy in patients with cancer and positive for hepatitis B virus (HBV) markers.Methods From January 2005 to January 2012,913 cancer patients were treated by chemotherapy including HBV-positive patients (HBV-positive group,288 cases) and HBV-negative patients (HBV-negative group,625 cases).The changes of hepatic function after chemotherapy between two groups were compared.Results The incidence of hepatic toxicity in HBV-positive group was higher than that in HBV-negative group [24.0％ (69/288) vs.11.4％ (71/625)],and there was significant difference between two groups (P＜ 0.01).The incidence of degree 11Ⅲ-Ⅳ hepatic toxicity was 11.4％ (14/123) in HBV-DNA-positive patients and 0.6％ (4/625) in HBV-negative group.In a variety of chemotherapy,there was significant difference in the incidence of hepatic toxicity in TP(paclitaxel +cisplatin),CAF(cyclophosphamide + doxorubicin + fluorouracil),CHOP(cyclophosphamide + doxorubicin +vincristine + prednisone) between two groups (P ＜ 0.05).The incidence of hepatic toxicity was highest in TP,which was 34.6％ (18/52) in HBV-positive group and 16.5％ (20/121) in HBV-negative group.Conclusion HBV infection is associated with higher risk of hepatic toxicity in patients with cancer during chemotherapy.

Clinical observation of modified CHOP regimen in the initial treatment of non-Hodgkin's lymphoma patients with low Karnofsky score / 白血病·淋巴瘤

Objective To observe the effecacy of modified CHOP regimen in the initial treatment of non-Hodgkin' slymphoma (NHL) patients with low Karnofsky score.Methods Twenty initial treatment NHI.patients with low Karnofsky score were randomly allocated into treatment group and control group,respectively treated with modified and standard CHOP regimen.Results Of 13 cases in treatment group,12 pacients'Karnofsky score were over 60.1 was still below 60,overall response (OR) rate was 92.3 ％ (12/13).while in control group,3 patients' Karnofsky score were over 60,4 were still below 60.OR rate was 100 ％ (7/7),rate of marrow toxicity was 57.1 ％ (4/7).There were no significantly difference for OR rates (P =0.4515),but for improving Karnofsky score there were significantly difference (P =0.0149).Conclusion Modified CHOP regimen can improve Karnofsky score of NHL patients with low Karnofsky score,benefical for further treatment and reducing hospitalization cost.